All News
Filter News
Found 180 articles
-
Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022
3/16/2022
Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close.
-
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Rallybio Corporation today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent corporate developments.
-
AI in the Pharmaceutical Market Size to Worth Around USD 9.24 Bn by 2030
3/14/2022
The global AI in pharmaceutical market size is expected to be worth around USD 9.24 billion by 2030 from valued at USD 905.91 million in 2021 with a CAGR of 29.4% from 2021 to 2030.
-
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery
3/10/2022
Exscientia and the University of Oxford Target Discovery Institute announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.
-
Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022
3/8/2022
Exscientia (Nasdaq: EXAI) today announced the acceptance of three abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
-
Exscientia to Present at Upcoming Investor Conferences in March 2022
2/22/2022
Exscientia announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March:
-
Intelligent Drug Discovery Market to Reach USD 3,711.8 Million by 2027 Growing at a CAGR of 39.4%, says Emergen Research
1/24/2022
The global Intelligent Drug Discovery Market is forecasted to be worth USD 3,711.8 Million by 2027, according to a current analysis by Emergen Research.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
1/19/2022
Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI.
-
Since Rallybio launched in 2018, the company has been laser-focused on the development of "transformative therapeutics" for patients suffering from rare and ultra-rare diseases.
-
Intelligent Drug Discovery Market Size to Reach USD 5,174.24 Million in 2028 Growing at a CAGR of 39.4%, according to Emergen Research
1/13/2022
According to Emergen Research, the global intelligent drug discovery market size was USD 360.90 million in 2020 and is expected to reach USD 5,174.24 million in 2028 and register a revenue CAGR of 39.4% during the forecast period, 2021-2028.
-
Sanofi has signed a collaboration deal with Exscientia to leverage the latter's artificial intelligence platform and develop up to 15 oncology and immunology therapies.
-
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
1/7/2022
Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples.
-
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022
1/6/2022
Rallybio Corporation today provided an update on recent accomplishments and announced expected upcoming milestones.
-
AI in Drug Discovery Market to Expand by 36.1% CAGR as Popularity of Mindful AI Offers Breakthrough Opportunities, Notes TMR
12/17/2021
According to the report, the global AI in drug discovery market was valued at US$ 0.35 Bn in 2020 and is projected to expand at a CAGR of 36.1% from 2021 to 2031.
-
Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
11/23/2021
Exscientia (Nasdaq: EXAI) today announced they will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).
-
Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update
11/11/2021
Evotec SE announced the financial results and corporate updates for the first nine months 2021.
-
Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021
11/10/2021
Exscientia will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 17, 2021 after U.S. market close.
-
Isomorphic Laboratories has expressed plans to foray into drug discovery and development by tapping into the technology of its sister company DeepMind.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look.